Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avita Medical ( (RCEL) ) has shared an announcement.
On April 30, 2026, AVITA Medical named longtime director Cary Vance as its permanent President and Chief Executive Officer, following his interim leadership since October 2025 and a formal search process. Vance’s appointment, which includes a three-year employment agreement with performance-based equity and bonus incentives, formalizes the management continuity that has stabilized operations and sharpened strategy in recent months.
The board simultaneously elevated veteran healthcare executive and director Jan Stern Reed to Chair, discontinuing her prior Lead Independent Director role in a shift to a more traditional governance structure. Together, the moves consolidate experienced leadership at a pivotal growth phase for AVITA’s wound care platform, signaling an emphasis on scaling product adoption and sustaining confidence among employees, clinicians, and investors.
Vance’s compensation package, which combines a $702,000 base salary with sizable equity grants vesting over three years and defined severance protections, is designed to align his incentives with long-term performance. The board highlighted his three decades of medical-technology leadership and recent success in stabilizing the business as key to positioning AVITA for its next stage of expansion in acute wound care markets.
The most recent analyst rating on (RCEL) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Avita Medical stock, see the RCEL Stock Forecast page.
Spark’s Take on RCEL Stock
According to Spark, TipRanks’ AI Analyst, RCEL is a Neutral.
The score is held back primarily by high-risk fundamentals: continued losses and cash burn alongside negative shareholders’ equity. It is partially offset by constructive earnings-call signals (2026 growth guidance, improving cash use and OpEx discipline, refinancing that reduces covenant risk) and a technically strong uptrend, though momentum indicators look overextended and valuation is constrained by negative earnings.
To see Spark’s full report on RCEL stock, click here.
More about Avita Medical
AVITA Medical, Inc. is a therapeutic acute wound care company focused on transforming outcomes in burn and trauma treatment. Its lead technology, the RECELL platform, creates Spray-On Skin from a patient’s own cells and is approved in major markets including the U.S., Europe, Australia, and Japan. The company also markets collagen-based and biosynthetic wound matrices, Cohealyx and PermeaDerm, primarily in the U.S.
Average Trading Volume: 225,476
Technical Sentiment Signal: Sell
Current Market Cap: $133M
For a thorough assessment of RCEL stock, go to TipRanks’ Stock Analysis page.